Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries


Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
23856511

DOI
10.1016/j.rmed.2013.06.007

Indexing Status
Subject indexing assigned by NLM

MeSH
Adrenergic beta-2 Receptor Agonists /economics /therapeutic use; Adult; Aged; Bronchodilator Agents /economics /therapeutic use; Cost of Illness; Cost-Benefit Analysis; Double-Blind Method; Drug Combinations; Drug Costs /statistics & numerical data; Drug Therapy, Combination; Ethanolamines /economics /therapeutic use; Formoterol Fumarate; Glucocorticoids /economics /therapeutic use; Health Care Costs /statistics & numerical data; Health Resources /utilization; Humans; Middle Aged; Pulmonary Disease, Chronic Obstructive /drug therapy /economics; Scandinavian and Nordic Countries; Scopolamine Derivatives /economics /therapeutic use; Sick Leave /statistics & numerical data; Tiotropium Bromide; Treatment Outcome

AccessionNumber
22013031541

Date bibliographic record published
23/08/2013